abrdn Life Sciences Investors (abrdn Life Sciences Investors) Sloan Ratio % : 0.00% (As of Sep. 2023)

View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

abrdn Life Sciences Investors's Sloan Ratio for the quarter that ended in Sep. 2023 was 0.00%.

As of Sep. 2023, abrdn Life Sciences Investors has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.

abrdn Life Sciences Investors Sloan Ratio % Historical Data

The historical data trend for abrdn Life Sciences Investors's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors Sloan Ratio % Chart

abrdn Life Sciences Investors Annual Data

Trend

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sloan Ratio %

Get a 7-Day Free Trial

abrdn Life Sciences Investors Semi-Annual Data
	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Sloan Ratio %	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of abrdn Life Sciences Investors's Sloan Ratio %

For the Asset Management subindustry, abrdn Life Sciences Investors's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

abrdn Life Sciences Investors's Sloan Ratio % Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's Sloan Ratio % falls into.

abrdn Life Sciences Investors Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

abrdn Life Sciences Investors's Sloan Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Sloan Ratio	=	(Net Income (A: Sep. 2023 )	-	Cash Flow from Operations (A: Sep. 2023 )
	-	Cash Flow from Investing (A: Sep. 2023 ))	/	Total Assets (A: Sep. 2023 )
	=	(22.352	-	0
	-	0)	/	402.6
	=	5.55%

abrdn Life Sciences Investors's Sloan Ratio for the quarter that ended in Sep. 2023 is calculated as

Sloan Ratio	=	(Net Income (TTM)	-	Cash Flow from Operations (TTM))
	-	Cash Flow from Investing (TTM))	/	Total Assets (Q: Sep. 2023 )
	=	(22.352	-	0
	-	0)	/	402.6
	=	5.55%

For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data. abrdn Life Sciences Investors's Net Income for the trailing twelve months (TTM) ended in Sep. 2023 was 33.803 (Mar. 2023 ) + -11.451 (Sep. 2023 ) = $22.35 Mil.
abrdn Life Sciences Investors's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2023 was 0 (Mar. 2023 ) + 0 (Sep. 2023 ) = $0.00 Mil.
abrdn Life Sciences Investors's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2023 was 0 (Mar. 2023 ) + 0 (Sep. 2023 ) = $0.00 Mil.

abrdn Life Sciences Investors (NYSE:HQL) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2023, abrdn Life Sciences Investors has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.

abrdn Life Sciences Investors Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » Sloan Ratio %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103

Website

https://www.abrdnhql.com

abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.

Executives

Todd Reit	director	C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Bill Maher	director	600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino	director	C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
James Joseph O'connor	other: Director of Adviser	C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze	other: Director of Adviser	C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc.	other: Adviser	1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick	other: Director of Adviser	C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar	officer: VP and Chief Legal Officer	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols	other: Director of Adviser	1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard	officer: President	ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy	officer: Secretary and Vice President	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari	officer: Treasurer and CFO	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson	officer: Vice President	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina	officer: Chief Compliance Officer & VP	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Stephen Bird	director	388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10022